CSL traded at 180.50 this Friday February 6th, decreasing 0.74 or 0.41 percent since the previous trading session. Looking back, over the last four weeks, CSL lost 6.18 percent. Over the last 12 months, its price fell by 33.11 percent. Looking ahead, we forecast CSL to be priced at 177.74 by the end of this quarter and at 167.13 in one year, according to Trading Economics global macro models projections and analysts expectations.
CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.